Table 3.
Univariate Cox proportional hazard regression analysis of prognostic factors associated with 28-day mortality in patients with confirmed SARS-CoV-2 infection
| Independent variable | HR (95% CI) | p value |
|---|---|---|
| FANA | 3.579 (1.481–8.648) | 0.005 |
| Sex | 1.093 (0.547–2.184) | 0.801 |
| Age (per 1-year) | 1.077 (1.041–1.114) | < 0.001 |
| Vaccination | 0.724 (0.338–1.551) | 0.406 |
| Cardiovascular disease | 1.225 (0.374–4.015) | 0.738 |
| Neurologic disease | 1.639 (0.713–3.768) | 0.245 |
| Malignant disease | 1.516 (0.683–3.366) | 0.307 |
| Renal disease | 1.882 (0.661–5.356) | 0.236 |
| Hepatic disease | 0.045 (0.000–34.957) | 0.362 |
| Pulmonary disease | 3.041 (1.070–8.643) | 0.037 |
| Hypertension | 2.717 (1.268–5.822) | 0.010 |
| Diabetes mellitus | 2.054 (1.046–4.032) | 0.036 |
| Organ transplantation | 1.881 (0.256–13.813) | 0.535 |
| C-reactive protein ≥ 45 mg/L | 5.077 (0.693–37.184) | 0.110 |
| Procalcitonin ≥ 0.200 ng/mL | 4.083 (1.905–8.752) | < 0.001 |
| Lactic acid ≥ 1.5 mmol/L | 1.359 (0.650–2.842) | 0.415 |
| D-dimer ≥ 1.5 μg/mL | 3.773 (1.707–8.338) | 0.001 |
| Ferritin ≥ 800 ng/mL | 2.065 (1.016–4.199) | 0.045 |
| Blood urea nitrogen > 20 mg/dL | 7.928 (2.419–25.984) | 0.001 |
| NT-pro BNP > 100 ng/L | 4.786 (1.144–20.022) | 0.032 |
| Initial O2 demand | 1.349 (0.652–2.789) | 0.419 |
| Remdesivir | 0.285 (0.141–0.576) | < 0.001 |
| Anticoagulant | 0.401 (0.174–0.922) | 0.032 |
| Dexamethasone | 0.811 (0.194–3.390) | 0.775 |
| Tocilizumab | 1.529 (0.779–3.000) | 0.217 |
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; HR, hazard ratio; CI, confidence interval; FANA, fluorescent antinuclear antibody; NT-pro BNP, N-terminal pro-brain natriuretic peptide.